Shares of Estée Lauder (NYSE:EL) Reckitt Benckiser (OTCPK:RBGPF) and Taro Pharmaceuticals (NYSE:TARO) came under pressure Wednesday after an independent U.S. laboratory said it found high levels of cancer-causing chemical benzene in some of the companies' acne treatments.
The New Haven, Connecticut-based lab Valisure, whose investigations into cancer risks related to heartburn drug Zantac promoted the U.S. FDA to pull the drug from the market in 2020, also filed a petition with the regulator calling for a similar action on the affected acne treatments.
According to Valisure, Taro (TARO) Proactiv, Estee Lauder's (EL) Clinique, Reckitt's (OTCPK:RBGLY) Cleansil and Target's (TGT) Up & Up had elevated levels of the carcinogen benzene, a natural component of gasoline that can cause leukemia in high amounts.
Reckitt (OTC:RBGPY) fell ~3% in London trading, while Estee Lauder (EL) and Taro (TARO) lost ~2% in the pre-market.
Taro (TARO), Target (TGT), Estee Lauder (EL), and Reckitt (OTCPK:RBGLY) didn't immediately respond to requests for comments. Sun Pharmaceuticals, which has agreed to take TARO private in a $43 per share deal, didn't immediately respond to Seeking Alpha email request for comment.
More on Estee Lauder, Reckitt Benckiser, etc.
- Reckitt Benckiser Group plc 2023 Q4 - Results - Earnings Call Presentation
- Reckitt Benckiser Group plc (RBGPF) Q4 2023 Earnings Call Transcript
- Reckitt Benckiser Group plc (RBGPF) CAGNY 2024 Conference Call Transcript
- Navigating the travel retail beauty outlook in the Middle Kingdom
- Biggest stock movers today: Nvidia, Air Products and Chemicals, Estee Lauder, 4D Molecular Therapeutics, and more